Pfizer to Make $54 Billion Off Treating COVID Over and Over

/

(Source: Dr. Joseph Mercola)

Pfizer expects record profits in 2022 due to its COVID-19 shots and antiviral medication.

STORY AT-A-GLANCE

 

  • Pfizer is expecting record-high revenue in 2022, courtesy of COVID-19

  • It’s predicting $32 billion in profits from its COVID-19 shots and another $22 billion from Paxlovid, for a total of $54 billion

  • Overall, Pfizer forecasted 2022 sales of $98 billion to $102 billion

  • First, Pfizer profits from the shots; next, when they don’t work to prevent infection, the company makes more money by selling pills to treat the infection

  • Many people experience a rebound of COVID-19 after taking Paxlovid, which means multiple courses of the drug are often necessary; this is bad news for the public but great news for Pfizer and its shareholders

While the world was plunged into a time of economic instability and panic during the COVID-19 pandemic, pharmaceutical companies like Pfizer made out like bandits and continue to reap the astonishing profits of their ineffective COVID-19 treatments. Ironically, part of what makes the treatments so profitable is the fact that they don’t do what they’re supposed to, which is prevent and effectively treat COVID-19.

Read Full Story